ARQT
Arcutis Biotherapeutics, Inc.
October 15, 2026 · market open
- Rarity
- 1.74
- Peak move
- +11.44%
- Float cap
- $2.9B
Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for immune-mediated dermatological diseases. It markets ZORYVE cream and foam, once-daily steroid-free PDE4 inhibitors, for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis in adults and pediatric patients. It sells primarily to dermatology and primary care prescribers and patients in the United States and Canada, with licensing partners in Greater China, Southeast Asia, and Japan.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
2 events · 0 from SEC or newswire · 0 timed with the moveanalyst_ratingCantor Fitzgerald analyst Steve Seedhouse initiated coverage of Arcutis Biotherapeutics with an Overweight rating and a $48 price target, citing the Zoryve dermatology franchise, HS and vitiligo trials, and pipeline asset ARQ-234.
institutional_flowPerpetual Ltd cut its Arcutis Biotherapeutics stake by 13.6% in the third quarter, selling 150,814 shares and retaining 958,843 shares worth approximately $25.3 million.